Thomas E. Stinchcombe, MD

Thomas E. Stinchcombe, MD, discusses the results of the randomized phase III ALTA-1L trial in ALK-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, discusses the importance of molecular testing in ALK-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, discusses remaining challenges in ALK-positive non­–small cell lung cancer.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the differences in toxicity profiles between brigatinib (Alunbrig) and alectinib (Alecensa) in ALK-positive non–small cell lung cancer (NSCLC).

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the benefit of alectinib in the treatment of patients with ALK-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses pivotal trials that have reshaped the standard of care in non–small cell lung cancer (NSCLC).

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the KEYNOTE-189 trial in patients with lung cancer.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the PACIFIC trial for patients with non–small cell lung cancer (NSCLC).